EC Number   |
Application |
Reference |
|---|
   3.4.23.49 | biotechnology |
engineering of enzyme variants with targeted, high substrate specificity |
663249 |
| 3.4.23.49 | biotechnology |
OmpT protease could be a possible factor responsible for reducing the expression of GFP at 37°C for wildtype GFP clone in K12 hosts like DH5alpha, JM109, LE 392 |
709830 |
| 3.4.23.49 | biotechnology |
utilization of outer-membrane endoprotease OmpT variants as processing enzymes for production of peptides from designer fusion proteins, e.g. useful in motilin production, overview |
660757 |
| 3.4.23.49 | food industry |
the peptidase shows maximal milk clotting activity at 60-65 °C and maintenance of enzymatic activity above 80% in the presence of 20 mM CaCl2 |
742551 |
| 3.4.23.49 | medicine |
the different contributions of EHEC and EPEC strains OmpT to the degradation and inactivation of antimicrobial peptide LL-37 may be due to their adaptation to their respective niches within the host, the colon and small intestine, respectively, where the environmental cues and abundance of antimicrobial peptides are different |
-, 717663 |
| 3.4.23.49 | medicine |
the enzyme is a target for vaccine development. B-cell epitope mapping with human sera, three-dimensional modeling, omptins allergenicity and antigenicity prediction, overview |
-, 755636 |
| 3.4.23.49 | medicine |
use in therapeutic peptide production, efficient cleavage of substrates with basic amino acids at the P4 and P6 positions, able to cleave efficiently a fusion protein carrying human glucagon-like peptide I, releases mature protein from an Escherichia coli expressed fusion protein carrying human atrial natriuretic peptide, a drug for acute congestive heart failure |
650667 |
| 3.4.23.49 | pharmacology |
studies on treatment of infection by antibiotic-resistant bacteria |
683820 |
